All In MedTech

FDA Clearance Tracker · P160054

HeartMate 3™ Left Ventricular Assist System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Aug 23, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Aug 23, 2017

Approved

Time to decision

261 days

Received Dec 5, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P160054
Device name
HeartMate 3™ Left Ventricular Assist System
Applicant location
Pleasanton, CA
Received
Dec 5, 2016
Decided
Aug 23, 2017
Decision
Approved
Supplements
132 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code DSQ

FDA's approval statement

As written in FDA's record.

Approval for the HeartMate 3 Left Ventricular Assist System. This device is indicated for providing short-term hemodynamic support (e.g., bridge to transplant or bridge to myocardial recovery) in patients with advanced refractory left ventricular heart failure.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code DSQ. The earliest in FDA's data is P900023, decided Nov 20, 1992.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.